Abstract
The high incidence of vascular complications in severe hyperhomocysteinaemia in homozygotes for cystathionine β-synthase deficiency has focused attention upon homocysteine as an atherogenic and thrombophilic agent. For two decades there has been accumulating evidence of mild hyperhomocysteinaemia as risk factor of vascular disease. Pooled data on hundreds of coronary, cerebrovascular and peripheral arterial disease patients show that mild hyperhomocysteinaemia was detectable in about 20-30%. In a recent meta-analysis of 27 studies up to 1994, including about 4000 patients and as many controls, it is calculated that the summary odds ratio of elevated homocysteine levels was 1.7, with 95% confidence interval (CI) 1.5-1.9, for coronary heart disease; it was 2.5, with 95% CI 2.0-3.0, for cerebro-vascular disease; and it was 6.8, with 95% CI 2.9-15.8, for peripheral vascular disease. The relevance of this newly recognized risk factor will be demonstrated by the outcome of the European Comac study on ‘Hyperhomocysteinaemia and Vascular Disease’, a multicentre case-control study on 800 vascular patients and 750 controls. Despite the selection for epidemiological reasons of a relatively low cut-off level as the criterion for mild hyperhomocysteinaemia in this study - the upper 20% of the distribution of control levels - the relative risk of thus-defined hyperhomocysteinaemia for arterial disease is about 2. This equals the relative risk of hypercholesterolaemia and of smoking; hypertension leads to a higher excess risk. The observed synergistic interaction between hyperhomocysteinaemia and hypertension and smoking may warrant a change in the now generally followed procedure of screening for hyperhomocysteinaemia only if conventional risk factors have not been detected in the patient. Those vascular patients with combined risk factors leading to synergism in their joint effect may profit most from homocysteine-lowering intervention.
Similar content being viewed by others
REFERENCES
Bienvenu T, Ankri A, Chadefaux B, et al (1991) Dosage de l'homocysteine plasmatique dans l'exploration des thromboses du sujet jeune. Presse Med 20: 985–988.
Boers GHJ (1986) Homocystinuria, a risk factor of premature vascular disease. Clinical Research Series, No. 3. Dordrecht/Riverton: Foris Publications.
Boers GHJ (1994) Hyperhomocysteinemia: a newly recognized risk factor for vascular disease. Neth J Med 45: 34–41.
Boers GHJ, Schoonderwaldt HC, Schulte PBM, Trijbels JMF, Smals AGH, Kloppenborg PWC (1983) Heterozygosity for homocystinuria: a risk factor of occlusive cerebrovascular disease? Clin Genet 24: 300–301.
Boers GHJ, Smals AGH, Trijbels JMF, et al (1985) Heterozygosity for homocystinuria in premature peripheral and cerebral occlusive arterial disease. N Engl J Med 313: 709–715.
Boushey CJ, Beresford SAA, Omenn GS, et al (1995) A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. J Am Med Assoc 274: 1049–1057.
Brattström L, Tengborn L, Lagerstedt C, et al (1991) Plasma homocysteine in venous thromboembolism. Haemostasis 21: 51–57.
Clarke R, Daly L, Robinson K, et al (1991) Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med 324: 1149–1155.
Daly LE, Meleady R, Graham IM (1995) Fasting or post methionine load homocysteine: which should be measured in relation to vascular risk? (Abstract) Irish J Med Sci 164(supplement 15): 6–7.
D'Angelo A, Fermo I, d'Angelo SV (1996) Thrombophilia, homocystinuria, and mutation of the factor V gene (Letter). N Engl J Med 335: 289.
Falcon CR, Cattaneo M, Panzeri D, et al (1994) High prevalence of hyperhomocysteinemia in patients with juvenile venous thrombosis. Arterioscler Thromb 14: 1080–1083.
Graham IM, Daly LE, Refsum HM, et al (1997) Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. J Am Med Assoc, in press.
den Heijer M, Blom HJ, Gerrits WBJ, et al (1995) Is hyperhomocysteinemia a risk factor for recurrent venous thrombosis? Lancet 345: 882–885.
den Heijer M, Koster T, Blom HJ, et al (1996) Hyperhomocysteinemia as a risk factor for deep vein thrombosis. N Engl J Med 334: 759–762.
Kluijtmans LAJ, van de Heuvel LPWJ, Boers GHJ, et al (1996) Molecular genetic analysis in mild hyperhomocysteinemia: a common mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for cardiovascular disease. Am J Hum Genet 58: 35–41.
Mandel H, Brenner B, Berant M, et al (1996) Coexistence of hereditary homocystinuria and factor V Leiden, effect on thrombosis. N Engl J Med 334: 763–768.
Mudd SH, Skovby F, Levy HL, et al (1985) The natural history of homocystinuria due to cystathionine-β-synthase deficiency. Am J Hum Genet 37: 1–31.
Mudd SH, Levy HL, Skovby F (1995) Disorders of transsulfuration. In Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic and Molecular Bases of Inherited Disease, 7th edn. New York: McGraw-Hill, 1279–1327.
Quéré I, Lamarti H, Chadefaux-Vekemans B (1996) Thrombophilia, homocystinuria, and mutation of the factor V gene (Letter). N Engl J Med 335: 289.
Rees MM, Rodgers GM (1993) Homocysteinemia: association of a metabolic disorder with vascular disease and thrombosis. Thromb Res 71: 337–359.
Sardharwalla IB, Fowler B, Robinson AJ, Komrower GM (1974) Detection of heterozygotes for homocystinuria. Arch Dis Child 49: 553–559.
Ueland PM, Refsum H, Brattström L (1992) Plasma homocysteine and cardiovascular disease. In Francis RB Jr, ed. Atherosclerotic Cardiovascular Disease, Hemostasis and Endothelial Function. New York: Marcel Dekker, 183–236.
Wilcken DEL, Wilcken B. The pathogenesis of coronary artery disease. A possible role for methionine metabolism. J Clin Invest 57: 211–215.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Boers, G.H.J. The case for mild hyperhomocysteinaemia as a risk factor. J Inherit Metab Dis 20, 301–306 (1997). https://doi.org/10.1023/A:1005325326802
Issue Date:
DOI: https://doi.org/10.1023/A:1005325326802